antibody (ICA)-positive non-diabetic and 4/34 (12%) ICA-negative subjects with metabolic abnormalities were GAD-AAb positive. These results show the association between type I (insulin-dependent) diabetes mellitus and the occurrence of GAD65-AAb, which possibly predicts a risk of developing the disease. Type I (insulin-dependent) diabetes mellitus is an organspecific autoimmune disease resulting from the specific destruction of pancreatic beta cells. In addition to beta cell-reactive T-cell clones (1) . autoantibodies (AAb) reactive with insulin and islet cell antibodies (ICA) or surface islet cell antigens (ICSA) were detected in newly diagnosed type I diabetic patients (reviewed in Ref. 2 ).
These disease-relevant autoantigen(s) include a 64-kD islet cell protein detected by immunoprecipitation from pancreatic islets (3) by sera from type I diabetic patients and identified as the gamma-aminobutyric acid (GABA)-synthesizing enzyme glutamate decarboxylase (GAD) (4) . There are at least two isoforms of GAD, which differ in their molecular size (65 and 67kD, respectively) and amino acid sequence and were derived from two genes located on two different chromosomes (5) (6) (7) . The homology between these two isoforms is approximately 65%; the differences are mainly found at the N-terminus (5) .
Autoantibodies against the 64-kD (GAD65) autoantigen occur years before clinical onset of type I diabetes mellitus (8) and seem to have a predictive value for the onset of the disease in the range of that of ICA (9) (10) (11) . However, all of these studies included only a small number of probands and were done using the material-and time-consuming method of autoradiography after immunoprecipitation of metabolically labelled islet proteins. Recently, two radioimmunoassays using native GAD from pig brain (12, 13) and an ELISA using recombinant GAD67 (14) were established for the detection of autoantibodies to GAD.
The aim of our study was to establish a radio¬ immunoassay as a rapid and sensitive method for the detection of autoantibodies to GAD using 12,I-labelled recombinant human GAD(,5 and to evaluate this assay in a cross-sectional study that (Fig. 1) (Fig. 1) . The binding of the GAD65-AAb-positive sera of 125I-GAD65 was closely associated with the end-point dilution, which was still detected to be positive, as shown in the dilution curves of 5 AAb-positive sera (Fig. 2) .
The addition of 2 5 µ of GAD-containing in contrast to GAD-depleted 100 000 g supernatant from rat brain resulted in a significant reduction in the binding of GAD65-AAb-positive sera (N = 30) from type I diabetic patients of 'I-GAD65 (mean binding 5.4 ± 0.96% vs 2.06 ± 0.78%, < 0.01) (Fig. 3) . No serum exceeded the cut-off after displacement. The mean binding of GAD65-AAb-negative sera (N = 21) from type I diabetic patients was unaffected by the displacement step (mean binding 1.82 ±0.4% vs 1.54 ± 0.29%; NS) (Fig. 3) . There was no correlation between the prevalence of GAD65-AAb and sex in all groups studied (Table 1) . Of the 12 ICA-positive non-diabetic subjects, only those with additional metabolic abnormalities and/or ICA of > 20 JDF units were found to be GAD^-AAb-positive.
Discussion
Previous studies have suggested that autoantibodies to (12) and 59% (13) for GAD65-AAb and 46% (14) for GAD67-AAb. The specificity of our assay system is comparable to the other immunoassays (0% (12), 2.5% (13) (10, 11) . This shows that GAD65-AAb are possibly a marker for a high risk of developing the disease. Additionally, we found 12% (4/ 34) of the subjects (all four first-degree relatives of type I diabetic patients) with metabolic abnormalities to be positive (two with impaired glucose tolerance and two with diminished insulin secretion in the first phase).
There was no association of GAD autoantibodies with the two kinds of metabolic abnormalities studied here. (34) .
Altogether, these results, obtained with the estab¬ lished radioimmunoassay, characterize the assay as a useful tool for detecting autoantibodies to GAD. The assay can be used for screening a large group of individuals with good reproducibility. Longitudinal studies are necessary to evaluate the predictive value of GAD autoantibodies detected by this assay for the development of type I diabetes. To examine the prevalence and the predictive value of GAD isoform-specific autoantibodies, it is necessary to establish an immunoassay for GAD65-AAb. This will make it possible to differentiate between GAD isoform-specific autoantibodies and autoantibodies that react with both isoforms.
